Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In trading on Wednesday, shares of Amgen crossed above their 200 day moving average of $287.75, changing hands as high as $296.76 per share. Amgen shares are currently trading up about 5% on the day.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen Inc. (NASDAQ:AMGN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 10:15 AM EDT Company Participants Adam Elinoff Paul Burton - Senior VP & Chief Medical Officer Casey Capparelli Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst So we have Paul Burton. He's the Chief Medical Officer of the company; and dabbing for the first time, Adam Elinoff, the new IR at Amgen.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.
Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.